Calls under review
Cancer Mission 2026 evaluation results are expected to be communicated on 18 December 2026 at the earliest.
The “Test and Demonstration of Multimodal Data Approaches for Personalised Medicine (MultiPMData2026)’ RITC call has ended and outcomes have been communicated. Successful applicants should engage with the HRB regarding the next steps at national level.
European Rare Diseases Research Alliance (ERDERA) Joint Transnational Call (JTC) 2026
‘Resolving unsolved cases in rare genetic and non-genetic diseases’ is the ERDERA JTC 2026 call topic. Results are expected towards the end of the year.
Open Calls
Horizon Europe Health Cluster 2027
The Horizon Europe Health Cluster 2026-2027 Work Programme is published.
The online Cluster Health Horizon Europe brokerage event 2027 is taking place next 24 and 25 November. Register now here. The 2027 HE Health Info Day (online) will be back-to-back on 26 November.
2027 Single Stage – set 1 of 2027 calls:
Update in opening and closing dates: open on 29 Oct 2026 and close on 17 Feb 2027.
HORIZON-HLTH-2027-01-STAYHLTH-01: Addressing disabilities through the life course to support independent living and inclusion
HORIZON-HLTH-2027-01-ENVHLTH-02: Integrating climate-related exposures into the human exposome and characterising its changes in response to climate change
HORIZON-HLTH-2027-01-ENVHLTH-MISSCLIMA-03: Tools and technologies to support health adaptation to climate change (PCP)
HORIZON-HLTH-2027-01-DISEASE-05: Development of novel small molecule antiviral therapeutics for pathogens with epidemic potential
HORIZON-HLTH-2027-01-DISEASE-06: Development of monoclonal antibodies to prevent and treat infections from Flaviviruses
HORIZON-HLTH-2027-01-DISEASE-07: Development of monoclonal antibodies to prevent and treat infections from Filo-, Nairo-, Phenui-, Picorna- and Toga viruses
HORIZON-HLTH-2027-01-DISEASE-08: Development of innovative antimicrobials against pathogens resistant to antimicrobials
HORIZON-HLTH-2027-01-DISEASE-10: Prevention and management of chronic non-communicable diseases in children and young people (GACD)
HORIZON-HLTH-2027-01-CARE-02: Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications
HORIZON-HLTH-2027-01-IND-01: Development of cell-free protein synthesis platforms for discovery and/or production of biologicals
2027 two-Stage calls – set 2 of 2027 calls
Update in opening and closing dates: 1st stage opens on 29 Oct 2026 and close on 17 Feb 2027.
HORIZON-HLTH-2027-02-DISEASE-01-two-stage: Innovative healthcare interventions for non-communicable diseases
HORIZON-HLTH-2027-02-DISEASE-14- two-stage: Clinical trials for advancing innovative interventions for neurodegenerative diseases
HORIZON-HLTH-2027-02-TOOL-01-two-stage: Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable disease
HORIZON-HLTH-2027-02-IND-02-two-stage: Portable and versatile Point-of-care diagnostics (IA)
EU4Health 2025 Work Programme – Open calls for Tender
HADEA/2026/OP/0020: Capacity Reservation for Personal Protective Equipment (EUFAB+PPE) pilot. Publication date 22 July 2026; deadline 8 December 2026; indicative budget €34 million.
EU Partnerships
European Rare Disease Research Alliance (ERDERA) Networking Support Scheme
The Networking Support Scheme (NSS) is a continuously open call designed to knit together researchers, clinicians and patient advocates working on rare diseases and rare cancers. Proposals may be lodged at any time.
Under the scheme, applicants can request up to €30,000 per networking event to cover meeting costs, travel costs, hybrid-meeting platforms and other essentials. Rounds will be held every six months until April 2029 – or until the dedicated budget is exhausted – providing a response pathway for emerging collaborations of the partnership.
European Rare Disease Research Alliance (ERDERA) Clinical Trial Call 2026
ERDERA opened its Clinical Trial Call 2026 (ECTC) on 1 July 2026 to support multinational, GCP‑compliant Phase I, Phase I/II and Phase II interventional clinical trials in rare diseases.
This call aims to generate robust clinical evidence and, where appropriate, data of regulatory relevance to support future regulatory interactions and subsequent clinical development. It is designed for rare disease trials where patient populations are often small and geographically dispersed, making multinational collaboration essential.
ERDERA hosted an information webinar on 6 July and Expressions of Interest closed on 10 September 2026. For further information visit CTC 2026 ERDERA.
See our Grant updates story for information on Joint Transnational Calls funded through European Partnerships.
The 2027 joint transnational call titled “Catalysing Collaborative Research for Recently Identified Rare Diseases” has been pre-announced to launch on 22 October 2026. The call aims to stimulate research interest and catalyse new collaborative initiatives centred on recently identified RDs that remain scientifically underserved. By advancing the understanding of natural history and disease pathomechanisms, and by fostering the development of relevant disease models, the overarching aim is to generate the foundational knowledge required to accelerate future therapeutic development.
An information webinar will occur on 14 December 2026 with pre-proposal submission closing on 1 Feb 2027. Applicants from Ireland should refer to the HRB call webpage after the call launches. For further information see also: ERDERA JTC 2027
Upcoming Calls
EU4Health
The EU4Health 2026 Work Programme has been published on 19 October 2026 and is available here.
The tentative call calendar should be published on HaDEA’s webpage soon and will be updated with more specific timelines in due course.
Horizon Europe Health Cluster 2027
2027 Single Stage calls – set 3 of 2027 calls
Calls open 3 June 2027 and close 16 Sept 2027.
HORIZON-HLTH-2027-03-TOOL-02: Advancing bio-printing of living cells for regenerative medicine
HORIZON-HLTH-2027-03-TOOL-04: Virtual Human Twins (VHTs) for integrated clinical decision support in prevention and diagnosis
HORIZON-HLTH-2027-03-TOOL-08: Towards Artificial General Intelligence (AGI) for healthcare (CSA)
EU Cancer Mission 2026 – 2027
The EU Cancer Mission 2026-2027 Work Programme is now published.
2027 opportunities for cancer researchers include:
2027 Single Stage calls
Calls open 10 February 2027 and close 21 Sept 2027.
HORIZON-MISS-2027-02-CANCER-01: Leveraging functional genomics to reveal novel targets for cancer treatment
HORIZON-MISS-2027-02-CANCER-02: Clinical research by Comprehensive Cancer Infrastructures for the benefit of patients with common cancers (IA)
HORIZON-MISS-2027-02-CANCER-03: Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multimodal treatment interventions for patients with rare or very rare cancers or cancer subtypes
HORIZON-MISS-2027-02-CANCER-04: Improving equitable health outcomes and added value for and with cancer patients through health-economics research, health systems research and outcomes research
HORIZON-MISS-2027-02-CANCER-05: Precommercial procurement of affordable solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines (PCP)
HORIZON-MISS-2027-02-CANCER-06: Support a Young Cancer Survivor Quality of Life (QoL) research programme by cancer charities and funding agencies
HORIZON-MISS-2027-06-SOIL-CANCER: Living labs to monitor and mitigate carcinogenic substances in and originating from soils: Evaluating their effects on human cancer risks
See also the HRB website for general information on the Horizon Europe and EU4Health programmes.
